3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Breast Neoplasms
1
Interventions
Specimen Handling
602
pembrolizumab
557
Magnetic Resonance Spectroscopy
527
Carboplatin
422
Cyclophosphamide
370
Cisplatin
369
Biopsy
349
Paclitaxel
304
Gemcitabine
299
Nivolumab
298
Radiotherapy
256
Bevacizumab
232
Dexamethasone
207
fludarabine
203
Docetaxel
185
durvalumab
177
atezolizumab
172
Oxaliplatin
170
Fluorouracil
166
venetoclax
164
Rituximab
163
Pemetrexed
161
Doxorubicin
157
Radiation
155
Capecitabine
155
Radiosurgery
145
Etoposide
137
Leucovorin
133
Ipilimumab
132
Lenalidomide
129
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
trastuzumab duocarmazine
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled